Immuntherapie des nichtkleinzelligen Lungenkarzinoms (NSCLC)
Authors:
- 15 June 2022
- journal article
- review article
- Published by Springer Nature in Die Innere Medizin
- Vol. 63 (7) , 709-716
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLCNew England Journal of Medicine, 2018
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice GuidelineJournal of Clinical Oncology, 2018
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung CancerNew England Journal of Medicine, 2018
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung CancerNew England Journal of Medicine, 2017
- Interlaboratory concordance of PD‐L1 immunohistochemistry for non‐small‐cell lung cancerHistopathology, 2017
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerNew England Journal of Medicine, 2016
- Dual Faces of IFNγ in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor ImmunityClinical Cancer Research, 2016
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paperAnnals of Oncology, 2015
- Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpointThe Lancet Oncology, 2014
- Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessmentJournal of Cancer Research and Clinical Oncology, 1997